KRAS, NRAS and BRAF mutation profiling in a series of 90 metastasic colorectal cancer spanish patients. An estimation of cost savings.
Rodón Natalia1, Román Ruth1, Verdú Montse1,2, Montes Mª del Mar3, García-Peláez Beatriz1, Diaz Olga1, Lacasa Carmen3 and Puig Xavier1,2.
1 BIOPAT. Biopatologia Molecular S.L., Barcelona (Spain). 2 HISTOPAT Laboratoris S.L., Barcelona (Spain). 3 Departamento de Farmacia. Hospital de Barcelona (SCIAS), Grup Assistència, Barcelona (Spain).
Background: Metastasic colorectal cancer (mCRC) patients harbouring a mutation in codon 12 or 13 of the KRAS does not benefit from therapy with antibodies targeting epidermal growth factor receptor (EGFR). Recently, several studies have shown that an extended study […]